Epidemiologic features of borderline ovarian tumors in California: a population-based study
- 322 Downloads
Borderline ovarian tumors (BOT) became no longer reportable in 2001, and few registries still collect information on these still poorly understood tumors. This study’s objective was to describe epidemiologic features, trends, and survival of BOTs compared with those of low-grade (LG) and high-grade (HG) epithelial ovarian cancer (EOC) in the large and diverse population of California.
Data from the California Cancer Registry were used to examine demographic and tumor characteristics among women diagnosed with BOT (n = 9,786), LG-EOC (n = 3,656), and HG-EOC (n = 40,611) from 1988 to 2010. Annual percent changes in BOT and LG-EOC incidence rates were estimated using Joinpoint regression; 5-year relative survival was calculated for both BOTs and LG-EOCs by age, race/ethnicity, and histology.
Age-adjusted incidence rates of BOT in 2009 were 3.1, 2.3, 2.2, and 1.4 per 100,000 among whites, Latinas, African Americans, and Asian/Pacific Islanders, respectively. Incidence rates for LG-EOC decreased by 2.2 % per year; rates for BOT increased by 7.3 % per year until 1993, remained unchanged until 2006, and seemed to decline thereafter. Compared with LG-EOCs, BOTs were diagnosed in higher frequency among Latinas, at younger age, and were more likely to affect only one ovary. Overall, 5-year relative survival for BOT was 98.9 %; among women diagnosed with stage IV BOT, survival was 77.1 %.
In this study, differences between BOTs and LG-EOCs were marked but varied substantially by histologic subtype and were far less dramatic than differences between BOTs and HG-EOCs. Findings underscore the importance of understanding these enigmatic tumors.
KeywordsEpithelial ovarian cancer Borderline ovarian tumors Incidence rates Relative survival Race/ethnicity
The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201000036C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement #U58 DP003862-01 awarded to the California Department of Public Health.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Frederiksen K, Hogdall EV, Glud E, Christensen L, Hogdall CK, Blaakaer J et al (2006) Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study. Cancer Causes Control 17(6):821–829PubMedCrossRefGoogle Scholar
- 16.Fritz A, Percy C (2000) Introducing ICD-O-3: impact of the new edition. J Registry Manag 27(4):125–131Google Scholar
- 17.Fritz APC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (eds) (2000) ICD-O: international classification of diseases for oncology, 3rd edn. World Health Organization, GenevaGoogle Scholar
- 18.NAACCR Latino Research Work Group (2005) NAACCR guideline for enhancing hispanic/latino identification: revised NAACCR hispanic/latino identification algorithm [NHIA v2]. North American Association of Central Cancer Registries, Springfield, ILGoogle Scholar
- 23.Chao TM, Yen MS, Chao KC, Ng HT (1996) Epithelial ovarian tumors of borderline malignancy. Zhonghua Yi Xue Za Zhi (Taipei) 58(2):97–102Google Scholar
- 26.American Cancer Society, California Department of Public Health, California Cancer Registry. California Cancer facts and Figures (2011). American Cancer Society, California Division, Oakland, CAGoogle Scholar
- 33.Benito V, Lubrano A, Arencibia O, Medina N, Alvarez Eva E, Andujar M, et al (2010) Serous and mucinous borderline ovarian tumors: are there real differences between these two entities? Eur J Obstet Gynecol Reprod Biol 153(2):188–192Google Scholar
- 34.McCluggage WG (2010) The pathology of and controversial aspects of ovarian borderline tumours. Curr Opin Oncol 22(5):462–72Google Scholar